LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
08/04/2026
Back to search
Official data from USPTO
VALNEVA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
VALNEVA
ST13
US500000079138125Class
1, 5, 42
Filing
79138125
Registration
4686292
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
53
Latest update
08/04/2026
Trademark type
Word
Nice classes
1, 5, 42
Filing date
05/31/2013
Registration date
02/17/2015
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/09/2025
Last transaction
08/04/2026
Responsible office
United States Patent and Trademark Office
Status code
706
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
Saint Herblain, FR
Examiner
BUONGIORNO, CHRISTOPHER L
Law office
L10
Current location
TMEG LAW OFFICE 101
Holders and representatives
Holders
VALNEVA
VALNEVA
Representatives
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for use in industryscience and agricultureexcept fungicidesherbicidesinsecticides and parasiticides; molecules from biotechnologiesproteins in raw material for industrial usescientific or medical research; cells and cell lines for use in scientificlaboratorymedical research; nucleic acids for laboratory use; proteins in raw material form for scientific and medical research; recombinant proteins in raw material form for scientific and medical research; Biomedical compoundspeptide substrates and peptide antigens used in analyzing and detecting certain toxins for clinical or medical laboratory use; Biochemical preparations derived from blood serum used as growth promoters in tissue cultures and microbiological media; Biochemicalsantibodies and fragments thereof for in vitro scientific or research use; Chemicals for use in biotechnological product development; Cultures of microorganisms other than for medical and veterinary use; Biological preparations and bacteriological preparations for use in cell cultures other than for medical or veterinary use
Class 5
Pharmaceuticals for human and veterinary use for the treatment of autoimmune diseasesinflammationcancerinfectious diseasesdiseases of the central nervous systemcardiovascular diseasesneurodegenerative and chronic diseases; antibodies and fragments thereof for use in disease testing; cell culturesmicroorganisms and viruses for medical and veterinary use; diagnostic agents for medicalpharmaceutical and veterinary use; cells for medical or clinical use; culture media for cultivating microorganism cells for medical and veterinary use; adjuvants for medical or and veterinary use; pharmaceutical and veterinary preparations for medicalpharmaceutical and veterinary usepreparations of encapsulated cells which release antibodiesliving cells and microorganismsvaccinesviral vectorsproteinspeptidesenzymesnucleic acids or pharmaceutically active compounds for the treatment of cancerauto-immune disordersinfectious diseasesinflammatory diseasesneurological and genetic disordersbowel diseasesdigestion problems
Class 42
Scientific research services for medical purposes in the fields of autoimmune diseasesinflammationcancerinfectious diseasesdiseases of the central nervous systemcardiovascular diseasesneurodegenerative and chronic diseases; scientific research for medicalpharmaceutical and veterinary purposes in the fields of autoimmune diseasesinflammationcancerinfectious diseasesdiseases of the central nervous systemcardiovascular diseasesneurodegenerative and chronic diseases; scientific researchin particularin the fields of biologycellular and molecular biologybiotechnologybacteriologyimmunologygeneticsmedicinepharmacologyvirologychemistry; scientific research relating to vaccinesantibiotics and immunological products for human and veterinary use; research and development of new products for others; testinganalysisevaluation of the goods of others to assure compliance with industry standards in the scientificmedical and veterinary fields; development and design of laboratory instruments for scientific and industrial researchin particularto obtain and prepare cellscell linesvirusesproteinsanimal and human materials; development of vaccinesantibiotics and immunological products for human and veterinary use; scientific and technological servicesdiagnostic and prognostic analyses in the fields of cellscell linesanimal and human materialsmicroorganismsmolecules for scientific purposes; scientific researchpreparation of scientific experts opinions reports
Publications
History of USPTO decisions and trademark events.
53 publications found
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
07/09/2026
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
05/09/2025
71AG
REGISTERED-SEC.71 ACCEPTED
05/09/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/05/2025
ES71
TEAS SECTION 71 RECEIVED
12/27/2024
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
05/22/2024
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
04/25/2024
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
02/25/2024
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
02/17/2024
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
02/17/2024
RNWL
INTERNATIONAL REGISTRATION RENEWED
04/07/2023
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
11/03/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/15/2022
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
10/01/2022
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
11/30/2020
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
11/30/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/24/2020
ES75
TEAS SECTION 71 & 15 RECEIVED
07/08/2020
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
02/17/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/26/2019
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
12/13/2018
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
12/22/2016
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/31/2015
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/29/2015
FIMP
FINAL DISPOSITION PROCESSED
06/29/2015
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/17/2015
R.PR
REGISTERED-PRINCIPAL REGISTER
02/17/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/02/2014
PUBO
PUBLISHED FOR OPPOSITION
12/02/2014
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/12/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/29/2014
ALIE
ASSIGNED TO LIE
10/28/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/09/2014
XAEC
EXAMINER'S AMENDMENT ENTERED
10/09/2014
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/09/2014
GNEA
EXAMINERS AMENDMENT E-MAILED
10/09/2014
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/09/2014
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
04/24/2014
GNFR
FINAL REFUSAL E-MAILED
04/24/2014
CNFR
FINAL REFUSAL WRITTEN
04/24/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/09/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/09/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/09/2014
RFNT
REFUSAL PROCESSED BY IB
12/10/2013
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/20/2013
RFRR
REFUSAL PROCESSED BY MPU
11/20/2013
MAFR
APPLICATION FILING RECEIPT MAILED
11/19/2013
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/16/2013
CNRT
NON-FINAL ACTION WRITTEN
11/15/2013
DOCK
ASSIGNED TO EXAMINER
11/13/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/13/2013
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/11/2013
Continuous trademark protection
Get notified about every new filing that threatens VALNEVA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.